Jenburkt Pharmaceuticals announced the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at...
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for...
Jenburkt Pharmaceuticals announced the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at...
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for...
Jenburkt Pharmaceuticals announced the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at...
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for...